SCHEMBL1770841

SCHEMBL1770841

COc1cc(N)c(C)cc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
GAA P10253 1/20 0.50
GFER P55789 1/20 0.50
MAPT P10636 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HTR2A P28223 4/20 0.46
TAAR1 Q96RJ0 3/20 0.46
HTR2C P28335 1/20 0.46
CYP3A4 P08684 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 1/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680329 0.91 POLB (0.61) POLBL3MBTL1GAAGFERMAPT
SCHEMBL192738 0.86 POLB (0.67) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL29447103 0.86 POLB (0.67) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL3343872 0.84 POLB (0.54) POLBL3MBTL1GAAGFERMAPT
SCHEMBL23885270 0.84 POLB (0.58) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL4465544 0.84 POLB (0.78) POLBL3MBTL1GAAMAPTNPSR1
SCHEMBL30052469 0.84 POLB (0.58) POLBL3MBTL1MAPTNPSR1HTR2A
Hydrochloric Acid SCHEMBL1401340 0.84 POLB (0.64) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL2862226 0.83 L3MBTL1 (0.50) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL1225409 0.83 POLB (0.61) POLBL3MBTL1GAAGFERMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4694889-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES Acelot, Inc. (US) 2026-02-18 EP disclosed
WO-2025096463-A1 PLK4 MODULATORS VIBLIOME THERAPEUTICS, LLC (US) 2025-05-08 WO disclosed
EP-4466260-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2024-11-27 EP disclosed
WO-2024216203-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES ACELOT, INC. (US) 2024-10-17 WO disclosed
CN-118574821-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2024-08-30 CN disclosed
WO-2023139199-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-07-27 WO disclosed
WO-2022192162-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2022-09-15 WO disclosed
WO-2022192162-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2022-09-15 WO disclosed
US-11154058-B2 Fungicidal compositions SYNGENTA PARTICIPATIONS AG (CH) 2021-10-26 US disclosed
CN-110740644-B Fungicidal compositions 先正达参股股份有限公司 2021-09-28 CN disclosed
US-20110112063-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-05-12 US disclosed
US-20110112063-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-05-12 US disclosed
US-20110112063-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-05-12 US disclosed
EP-2318392-A2 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-05-11 EP disclosed
WO-2010002655-A2 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-01-07 WO disclosed
EP-0630367-B1 NOVEL ARYLINDAZOLES AND THEIR USE AS HERBICIDES ZENECA LTD (GB) 2000-07-05 EP disclosed
US-5928998-A PRE- AND POSTEMERGENCE HERBICIDES ZENECA LIMITED (GB) 1999-07-27 US disclosed
US-5444038-A Arylindazoles and their use as herbicides ZENECA LIMITED (GB) 1995-08-22 US disclosed
EP-0630367-A1 NOVEL ARYLINDAZOLES AND THEIR USE AS HERBICIDES ZENECA LIMITED (GB) 1994-12-28 EP disclosed
WO-1993018008-A1 NOVEL ARYLINDAZOLES AND THEIR USE AS HERBICIDES ZENECA LIMITED (GB) 1993-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154058-B2 Fungicidal compositions PFAS, NAT1, PAH POLB 3519/4885L3MBTL1 1805/4885GAA 1009/4885
US-20110112063-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IGF1R, TYMP, PDXK POLB 374/4885L3MBTL1 3896/4885GAA 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.